CERN Cerner Corporation

Cerner Finalizes Acquisition of Kantar Health

Cerner Finalizes Acquisition of Kantar Health

Pairing data and research expertise to revolutionize the discovery, development and commercialization of life sciences innovations

KANSAS CITY, Mo., April 01, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CERN), a global healthcare technology company, today announced the acquisition of Kantar Health, a division of Kantar Group, for $375 million in cash, subject to adjustment. Kantar Health’s rich life sciences expertise will be combined with Cerner’s robust collection of real-world data (RWD) and technology and is expected to accelerate innovation in life sciences research and improve patient outcomes worldwide.

“The promise of real-world evidence to power drug discovery is right in front of us,” said Donald Trigg, president, Cerner. “Kantar Health is an important next step in building out the capabilities our growing network of provider clients need to fundamentally change the time and cost for clinical trials.”

The highly experienced teams at Kantar Health bring deep understanding of the needs of the pharmaceutical and life sciences industry. Their research and consulting solutions, complemented by Cerner’s RWD, position Cerner to help life sciences companies and research organizations with all aspects of the therapeutic lifecycle.

The growing client consortium, which today represents 92 million patients and 776 million clinical encounters, will be able to engage more with life sciences companies for funded research studies. A stronger collaboration between providers and the pharmaceutical industry is enabled through this acquisition. It will help researchers generate more health insights and use differentiated RWD assets and expertise to address the most complex clinical research questions.

As a result of the transaction closing, the Kantar Health team located around the world is joining Cerner and will be integrated within its Strategic Growth business. This includes Kantar Health’s research and consulting solutions and global clients. Lynnette Cooke, head of Kantar Health, will continue to lead the team and join the Cerner leadership.  

“Kantar Health and Cerner’s Strategic Growth business have a great deal in common, starting with a vision to advance patient care around the world. Culturally, we share the same values when it comes to how we develop our people, our offer and our client base. I’m excited to continue leading the team as we integrate with Cerner,” said Cooke. “I have great admiration for Cerner’s health technologies and am inspired by their strategic vision for future growth. Our collective capabilities and assets will enable the acceleration of innovation and elevate our expertise in addressing the most complex clinical research questions changing the way healthcare is developed and delivered.”

About Cerner

health technologies connect people and information systems at thousands of contracted provider facilities worldwide dedicated to creating smarter and better care for individuals and communities. Recognized globally for innovation, Cerner assists clinicians in making care decisions and assists organizations in managing the health of their populations. The company also offers an integrated clinical and financial system to help manage day-to-day revenue functions, as well as a wide range of services to support clinical, financial and operational needs, focused on people. For more information, visit ,  or connect on , , ,  or . Nasdaq: CERN. Health care is too important to stay the same.

Contacts:

Cerner Investor Contact: Allan Kells, (816) 201-2445,

Cerner Media Contact: Stephanie Greenwood,

Kantar Media Contact: Ed Gemmell,

All statements in this press release that do not directly and exclusively relate to historical facts constitute forward-looking statements. These forward-looking statements are based on the current beliefs, expectations and assumptions of Cerner's management with respect to future events and are subject to a number of significant risks and uncertainties. It is important to note that Cerner's performance, and actual results, financial condition or business could differ materially from those expressed in such forward-looking statements. The words “expected” and “position”, or the negative of these words, variations thereof or similar expressions are intended to identify such forward-looking statements. For example, our forward-looking statements include statements regarding the future benefits or synergies of the transaction. Factors that could cause or contribute to such differences include, but are not limited to: risks inherent with business acquisitions and integrations, such as difficulties and operational and financial risks associated with integrating Cerner and the acquired business generally and during the COVID-19 pandemic; the occurrence of any event, change or other circumstances that could make closing in a specific country impracticable; risks related to disruption of management time from ongoing business operations due to the transaction and integration; failure to realize the synergies, market opportunities and other benefits expected from the transaction; risk that the assets and business acquired may not continue to be commercially successful; the ability of Cerner and Kantar Health to retain customers and key personnel and to maintain relationships with key suppliers of the acquired business; unexpected costs, charges or expenses resulting from the transaction or the integration; litigation or claims relating to the transaction or the acquired assets and business; and the extent to which the COVID-19 pandemic and measures taken in response thereto could adversely affect the business acquired and the assumptions management has used in its evaluation of the transaction. Additional discussion of these and other risks, uncertainties and factors affecting Cerner's business is contained in Cerner's filings with the Securities and Exchange Commission. The reader should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made. Except as required by law, Cerner undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events, or changes in our business, results of operations or financial condition over time.



EN
01/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cerner Corporation

CERNER sees an upgrade to Slightly Positive due to a better fundamenta...

The general evaluation of CERNER (US), a company active in the Software industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date December 14, 2021, the closing price was USD 77.26 and...

 PRESS RELEASE

Cerner Announces Increased Quarterly Dividend

Cerner Announces Increased Quarterly Dividend Dividend of $0.27 per issued and outstanding share reflects 23% increase KANSAS CITY, Mo., Dec. 10, 2021 (GLOBE NEWSWIRE) --  (NASDAQ: CERN), a global healthcare technology company, today announced that its board of directors declared a cash dividend to stockholders of $0.27 per issued and outstanding share, up 23 percent from the prior quarterly dividend of $0.22. The cash dividend will be payable January 11, 2022, to shareholders of record as of the close of business December 27, 2021. Cerner intends to pay regular quarterly cash dividend...

 PRESS RELEASE

Cerner Names Nasim Afsar, MD MBA as Company’s First Chief Health Offic...

Cerner Names Nasim Afsar, MD MBA as Company’s First Chief Health Officer Experienced Clinical Executive to Lead Patient and Caregiver Experiences KANSAS CITY, Mo., Nov. 16, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CERN), a global healthcare technology company, today announced Nasim Afsar, MD, MBA, MHM, as the company’s first Chief Health Officer, effective January 2022. In this new role, Dr. Afsar will lead Cerner’s more than 1,000 healthcare professionals who provide insight and guidance to product development and improving the lives of patients and caregivers. She will also lead the quality...

 PRESS RELEASE

Cerner Reports Third Quarter 2021 Results

Cerner Reports Third Quarter 2021 Results Delivers Strong Results Across Key MetricsGAAP Operating Margin and Diluted EPS Lower; Adjusted Operating Margin and Adjusted Diluted EPS Both up Sharply vs. Year-Ago QuarterFull-Year Guidance Increased KANSAS CITY, Mo., Oct. 29, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CERN) today announced results for the 2021 third quarter that ended September 30, 2021. The third quarter 2021 earnings release can be viewed as well as on the company’s website at . Cerner will host an earnings conference call to provide additional detail on the Company’s results a...

 PRESS RELEASE

Cerner Enviza Aims To Accelerate Therapies And Improve Patient Outcome...

Cerner Enviza Aims To Accelerate Therapies And Improve Patient Outcomes Combining decades of healthcare, life sciences and collaborative research to transform the way care is delivered KANSAS CITY, Mo., Oct. 26, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CERN), a global healthcare technology company, announces the launch of a new operating unit, SM, that offers data-driven solutions and research services to help bring clarity to multi-dimensional data through real-world evidence and insights. The combined expertise of the Cerner and Kantar Health teams is expected to help accelerate discovery, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch